Pulmonary Arterial Hypertension Pipeline Insight Research Report | DelveInsight

Los Angeles, USA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Pulmonary Arterial Hypertension Pipeline Insight Research Report  

Around 55+ key companies are developing therapies for Pulmonary Arterial Hypertension, among which the drug of Liquidia Technologies is in the advanced stage (Pre Registration) 

DelveInsight's "Pulmonary Arterial Hypertension (PAH) Pipeline Insight" report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension pipeline landscapes. It comprises Pulmonary Arterial Hypertension pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Pulmonary Arterial Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Pulmonary Arterial Hypertension pipeline products.   

Some of the key takeaways from the Pulmonary Arterial Hypertension Pipeline Report  

• Major companies such as Galectin Therapeutics, Pfizer, Aerami Therapeutics, PhaseBio Pharmaceuticals, Bial, Gossamer Bio, Arena Pharmaceuticals, United Therapeutics, Acceleron Pharma, Bristol Myers Squibb, and others are developing potential drug candidates to improve the Pulmonary Arterial Hypertension treatment scenario. 
• The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH. 
• The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. In December 2020, Acceleron Pharma announced that the European Commission (EC) had granted orphan designation to sotatercept to treat patients with pulmonary arterial hypertension (PAH). Sotatercept is part of a licensing agreement with Bristol Myers Squibb. 
• The orphan drug, Flolan (epoprostenol sodium for injection or prostacyclin) has been approved as a standard long-term treatment of individuals with severe PAH.
• The FDA has granted the orphan drug treprostinil (Remodulin) in subcutaneous and intravenous forms and Tyvaso, an inhaled form of treprostinil, and oral form (Orenitram) for the treatment of PAH. 
• The FDA approved iloprost (Ventavis) for the PAH treatment. The treatment is inhaled via the mouth with the assistance of a special nebulizer, dilating the arteries and inhibiting the formation of blood clots. 
• Revatio (sildenafil), a phosphodiesterase type 5 (PDE5) inhibitor, also treats PAH.  
• In August 2021, United Therapeutics Corporation announced it would present data from a clinical trial studying Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH) at the European Respiratory Society (ERS) International Congress 2021, which will be held virtually from September 5-8, 2021.
• In July 2021, PulmoSIM Therapeutics (PulmoSIM) announced that it has entered into a strategic partnership with the investigators from National Jewish Health and Brown University for the clinical development of PT001. This drug targets multiple responsible pathways in PAH to provide curative treatment. 
• In June 2021, PulmoSIM Therapeutics (PulmoSIM) announced that the U.S. Food and Drug Administration (FDA) had granted orphan drug designation for asset PT001 for the treatment of Pulmonary Arterial Hypertension (PAH).
• In January 2021, PhaseBio Pharmaceuticals, Inc. announced the presentation of data from a Phase Ib/IIa pilot study highlighting three patients who received pemziviptadil (PB1046), the company's first-in-class, sustained-release vasoactive intestinal peptide (VIP) analog for the treatment of pulmonary arterial hypertension (PAH).

Get an overview of pipeline landscape @ Pulmonary Arterial Hypertension Clinical Trials Analysis 

Pulmonary Arterial Hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure in the arteries of the lungs for no apparent reason. 

Pulmonary Arterial Hypertension Emerging Drugs

• Sotatercept: Acceleron Pharma/Bristol Myers Squibb

Sotatercept is a first-in-class therapeutic fusion protein composed of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trials for the treatment of PAH.

• LIQ861: Liquidia Technologies

LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company's novel PRINT technology and engineered to enhance deep-lung delivery of treprostinil in PAH patients using a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).

• Seralutinib: Gossamer Bio

Gossamer Bio is developing Seralutinib (GB002) for the treatment of Pulmonary Arterial Hypertension. It is currently in the Phase II stage of development (NCT04456998). It acts as an inhibitor of Platelet-derived growth factor receptors,  CSF1R, c-KIT. 

• Zamicastat: Bial

Bial is developing Zamicastat for the treatment of Pulmonary Arterial Hypertension. It is currently in the Phase II stage of development (NCT04316143).  It acts as an inhibitor of Dopamine beta-hydroxylase. 

For further information, refer to the detailed report @ Pulmonary Arterial Hypertension Pipeline Therapeutics 

Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight    

• Coverage: Global 
• Major Players: 55+ Key Players
• Prominent Players: Galectin Therapeutics, Pfizer, Aerami Therapeutics, PhaseBio Pharmaceuticals, Bial, Gossamer Bio, Arena Pharmaceuticals, United Therapeutics, Acceleron Pharma, Bristol Myers Squibb, and many others.   
• Key Drugs Profiles: 55+ Products
• Phases:  

·       Pulmonary Arterial Hypertension Therapies Late-stage (Phase III)  
·       Pulmonary Arterial Hypertension Therapies Mid-stage (Phase II)
·       Pulmonary Arterial Hypertension Therapies Early-stage (Phase I) 
·       Pulmonary Arterial Hypertension Preclinical stage and Discovery candidates     
·       Discontinued and Inactive candidates  

• Mechanism of Action:

·      Epoprostenol receptor agonists
·      Activin inhibitors
·      Platelet-derived growth factor receptor antagonists
·      Dopamine beta-hydroxylase inhibitors
·      Vasoactive intestinal peptide type II receptor agonists
·      Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors 
·      Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
·      Galectin 3 inhibitors 

• Molecule Types:   

·     Peptides
·     Monoclonal antibodies
·    Small molecules 
·    Proteins
·    Gene therapy

• Route of Administration:

·     Parenteral 
·      Oral
·      Intravenous
·      Subcutaneous

• Product Types:

·       Monotherapy
·       Combination
·       Mono/Combination 

Key Questions regarding Current Pulmonary Arterial Hypertension Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  

• What are the current options for Pulmonary Arterial Hypertension treatment?
• How many companies are developing therapies for the treatment of Pulmonary Arterial Hypertension? 
• How many are Pulmonary Arterial Hypertension emerging therapies in the early-stage, mid-stage, and late development stages to treat Pulmonary Arterial Hypertension? 
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Pulmonary Arterial Hypertension market? 
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Pulmonary Arterial Hypertension?  
• What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Pulmonary Arterial Hypertension therapies? 
• What are the critical designations that have been granted for the emerging therapies for Pulmonary Arterial Hypertension? 
• How many patents are granted and pending for the emerging therapies to treat Pulmonary Arterial Hypertension?   

Table of Contents

Get a customized pipeline report @ Pulmonary Arterial Hypertension Drugs Pipeline Report  

Other Reports 

• Pulmonary Emphysema Market 
• Relapsing Multiple Sclerosis Market
• Glomerulonephritis Market
• Transcatheter Heart Valve Replacement Devices Market
• Bradycardia Treatment Devices Market
• Ischemia-reperfusion injury market

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

Contact Us:

Shruti Thakur 

info@delveinsight.com   

+1(919)321-6187 

www.delveinsight.com